Associate Director
Alexion
Associate Director
Alexion
Global biopharmaceuticals focusing on rare diseases
Associate Director, ATTR Marketing will lead the next phase of commercialization for ALXN2060 (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM). With the product now post-launch, the focus of the role is to accelerate patient identification, strengthen customer adoption, expand market share, and drive sustained business growth. This individual will refine and execute go-to-market strategies in partnership with Sales, Medical Affairs, Commercial Excellence, and other key stakeholders to maximize the brand's performance in a rapidly evolving market.
Date Posted
04-11月-2026Closing Date
30-12月-2026Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact [email protected]. Alexion participates in E-Verify.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion